Hanmi Pharm Co Ltd
KRX:128940
Hanmi Pharm Co Ltd
KRX:128940
Price:
549 000
KRW
-0.36%
Market Closed
Market Cap:
₩7T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hanmi Pharm Co Ltd
KRX:128940
|
KR |
|
Kunlun Energy Company Ltd
HKEX:135
|
HK |
|
Inspire Medical Systems Inc
NYSE:INSP
|
US |
|
Residential Secure Income PLC
LSE:RESI
|
UK |
|
Scatec ASA
OSE:SCATC
|
NO |
|
M
|
MS International PLC
LSE:MSI
|
UK |
|
Access-Power & Co Inc
OTC:ACCR
|
US |
|
H
|
Hybrid Financial Services Ltd
BSE:500262
|
IN |
|
AbraSilver Resource Corp
XTSX:ABRA
|
CA |
|
Caisse Regionale de Credit Agricole Mutuel Brie Picardie
PAR:CRBP2
|
FR |
|
Roblon A/S
CSE:RBLN B
|
DK |
|
NWF Group PLC
LSE:NWF
|
UK |
|
Airtac International Group
TWSE:1590
|
CN |
|
Great Eastern Holdings Ltd
OTC:GEHDF
|
SG |
|
M
|
Manulife US Real Estate Investment Trust
SGX:BTOU
|
SG |
Multiples-Based Value
The Multiples-Based Value of one
Hanmi Pharm Co Ltd
stock under the Base Case scenario is
hidden
KRW.
Compared to the current market price of 549 000 KRW,
Hanmi Pharm Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Hanmi Pharm Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Hanmi Pharm Co Ltd Competitors
Hanmi Pharm Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
|
Hanmi Pharm Co Ltd
KRX:128940
|
7T KRW | 4.5 | 41.1 | 20.1 | 27.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
